Ume'å scientist publishes new findings about origin of plague bacteriumApril 29, 2002A team including researchers at the Total Defense Research Institute, NBC Defense, in Ume'å, Sweden, and the Department of Molecular Biology, Ume'å University, are publishing in this week's issue of Science new findings that show that the protein Ymt is of crucial importance for the capacity of the plague bacterium to survive and spread the plague via flea vectors. Professor Ãke Forsberg and visiting researcher Dr. Peter Cherepanov are studying the properties that enable the plague bacterium Yersinia pestis to cause life-threatening infections in animals and humans. Increased knowledge of the mechanisms that Y. pestis exploits to conquer the body's immune defense can make it possible to develop new methods of treatment for serious infectious diseases. Historically, the plague is one of our most feared infectious diseases. During the most wide-spread epidemic in the middle ages, also known as the Black Death, more than 25% of the European population died. Today the disease is not very common, with some 2,000 cases per year. The plague occurs primarily in Africa and Asia, but there are also a few cases in North America every year. The bacteria are normally spread by fleas, first of all to rodents. Humans can also be infected by fleas. When the disease reaches the lungs of a human, the infection can be spread through the air to other people. The onset of the disease is rapid, with a high temperature and a headache. There is often an enlargement of the lymph glands located near the back of the jaw, which explains why it is also called the bubonic plague. Untreated, the infection quickly reaches the blood, leading to general blood poisoning. Mortality for untreated bubonic plague is over 50%. If the infection is spread by the air to the lungs, the course of the disease is even more rapid, and mortality for untreated lung plague is virtually 100%. The high rate of mortality, together with the rapid progression of the disease, places plague bacteria among those considered for use as a biological weapon. Y. pestis is very closely related to another bacterium called Y. pseudotuberculosis. The plague bacterium evolved from Y. pseudotuberculosis as recently as 1,500 to 2,000 years ago. Y. pseudotuberculosis leads to a relatively mild stomach infection in humans. The key to the capacity of the plague bacterium to cause fatal infections in humans lies in the differences between the two species of bacteria. The plague bacterium has two movable genetic elements, plasmids, that Y. pseudotuberculosis lacks. On one of these plasmids the research team has identified a gene that codes for a previously described "mouse toxin" that is seen as a major part of the explanation for the high potency of the plague bacterium in causing disease. The researchers have now shown that the gene, Ymt, is not at all involved in the infection of animals but instead is absolutely crucial to the ability of the bacterium to survive in fleas and thereby to spread the disease further. The ability to spread the disease via fleas represents a decisive step in the development of the plague bacterium. Thus, this ability arose in connection with the acquisition of the plasmid that hosts the Ymt gene. The Ume'å scientists arrived at these findings in collaboration with researchers from the Rocky Mountain Laboratories, NIH, Hamilton, and the University of Michigan Medical School, Ann Arbor, Michigan. VetenskapsrÃ¥det (The Swedish Research Council) |
|||||||||||||||||||||
| Related Tuberculosis Current Events and Tuberculosis News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. Drug industry, nonprofits join forces to fight world's neglected diseases Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. There's a speed limit to the pace of evolution, Penn biologists say Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits." Cell phones become handheld tools for global development Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. Scientists take step toward simple and portable tuberculosis tests for developing world Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years. More Tuberculosis Current Events and Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||